Enliven Therapeutics Future Growth
Future criteria checks 2/6
Enliven Therapeutics's earnings are forecast to decline at 21.8% per annum while its annual revenue is expected to grow at 73% per year. EPS is expected to decline by 15.9% per annum.
Key information
-21.8%
Earnings growth rate
-15.9%
EPS growth rate
Pharmaceuticals earnings growth | 27.6% |
Revenue growth rate | 73.0% |
Future return on equity | n/a |
Analyst coverage | Low |
Last updated | 10 Jun 2024 |
Recent future growth updates
Recent updates
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 0 | -168 | N/A | -131 | 3 |
12/31/2025 | 0 | -130 | N/A | -100 | 3 |
12/31/2024 | N/A | -103 | N/A | -79 | 3 |
3/31/2024 | N/A | -80 | -64 | -64 | N/A |
12/31/2023 | N/A | -72 | -61 | -61 | N/A |
9/30/2023 | N/A | -62 | -57 | -57 | N/A |
6/30/2023 | N/A | -52 | -48 | -47 | N/A |
3/31/2023 | N/A | -44 | -43 | -43 | N/A |
12/31/2022 | N/A | -38 | -33 | -32 | N/A |
9/30/2022 | N/A | -37 | -31 | -31 | N/A |
12/31/2021 | N/A | -25 | -19 | -19 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ELVN is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: ELVN is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: ELVN is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: ELVN's revenue (73% per year) is forecast to grow faster than the US market (8.7% per year).
High Growth Revenue: ELVN's revenue (73% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if ELVN's Return on Equity is forecast to be high in 3 years time